Sign up to save your podcasts
Or
Share Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
touchPANEL DISCUSSION for touchONCOLOGY
Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC.
The experts
- Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/her2-dysregulation-nsclc-targeted-therapy/
View all episodes
By touchpodcasttouchPANEL DISCUSSION for touchONCOLOGY
Listen to a panel of experts discuss the latest clinical research in HER2 dysregulation and potential HER2-targeted therapies in NSCLC.
The experts
- Prof. Egbert Smit – Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent educational grant from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website:
https://touchoncologyime.org/her2-dysregulation-nsclc-targeted-therapy/